Skip to main content
Premium Trial:

Request an Annual Quote

Cyntellect, SR Pharma, Galapagos, Indus, ProCitius

Premium

Cyntellect Awarded $500,000 Grant to Develop siRNA Transfection Technology

Cyntellect said this week that it has received about $500,000 from the National Science Foundation to further develop its laser-based siRNA transfection technology.

The technology, called LEAP for laser-enabling analysis and processing, uses a laser to temporarily permeabilize cells so that a variety of molecules, including siRNAs, can be transfected via a process termed opto-injection. The system's laser can also be used to destroy untransfected cells, so that researchers end up with a pure set of transfected cells.


SR Pharma Reports Preliminary Year-End Results

SR Pharma released last week preliminary financial results for 2005, reporting a pre-tax loss of £3.6 million ($6.5 million) on its £7.5 million acquisition of RNAi drugs shop Atugen last July (see RNAi News, 7/29/2005).

SR Pharma said it had £9.1 million in cash at the end of 2005, compared with £3.1 million at the end of 2004, reflecting a £10 million round of financing that closed in July.


Galapagos Inks Chemistry Services Deals with Indus, ProCitius

Galapagos said last week that it has signed chemistry outsourcing deals with Indus Biosciences and ProCitius.

According to Galapagos, both firms will carry put the chemistry services for BioFocus, with an option to provide support for client projects conducted by the BioFocus DPI Medicinal Chemistry division.

Additional terms were not disclosed.

"These strategic outsourcing agreements … complement our acquisition of DPI's drug discovery operations," Onno van de Stolpe, CEO of Galapagos, said in a statement.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.